Seeking Alpha
Value, growth, long-term horizon, medium-term horizon
Profile| Send Message| ()  

Do you prefer to invest with a stock's trading momentum? We ran a screen with that idea in mind.

We began by screening the drugmakers industry for stocks with strong momentum, trading within 5% of their 52-week highs.

We then screened for those stocks with strong sales trends, comparing growth in revenue to growth in accounts receivable. Since accounts receivable is the portion of revenue not yet received, and there is no guarantee the money will ever be received, the smaller the portion of revenue made up of receivables the healthier the company's revenue.

We screened for stocks seeing faster growth in revenue than accounts receivable year-over-year, as well as accounts receivable comprising a smaller portion of current assets over the same time period.

For an ‪interactive version of this chart, click on the image below. Analyst ratings sourced from Zacks Investment Research.‬

Tool provided by Kapitall (www.kapitall.com). More investing ideas on Kapitall Wire (wire.kapitall.com).

Do you think these stocks will break through to new highs? Use this list as a starting point for your own analysis.

List sorted by increase in revenue over the last year.

1. Par Pharmaceutical Companies Inc. (PRX): Engages in the development, manufacture, and distribution of generic and branded drugs in the United States. Market cap at $1.84B, most recent closing price at $49.87. The stock is trading 4.74% below its 52-week high. Revenue grew by 31.29% during the most recent quarter ($294.33M vs. $224.19M y/y). Accounts receivable grew by -9.96% during the same time period ($167.43M vs. $185.96M y/y). Receivables, as a percentage of current assets, decreased from 28.55% to 28.51% during the most recent quarter (comparing 3 months ending 2012-06-30 to 3 months ending 2011-06-30).

2. Watson Pharmaceuticals, Inc. (WPI): Engages in the development, manufacturing, marketing, sale, and distribution of generic and brand pharmaceutical products focused on urology and women's health in the United States, western Europe, Canada, Australasia, South America, and South Africa. Market cap at $10.2B, most recent closing price at $79.89. The stock is trading 1.01% below its 52-week high. Revenue grew by 25.28% during the most recent quarter ($1,355.2M vs. $1,081.7M y/y). Accounts receivable grew by 6.27% during the same time period ($876M vs. $824.3M y/y). Receivables, as a percentage of current assets, decreased from 41.1% to 37.76% during the most recent quarter (comparing 3 months ending 2012-06-30 to 3 months ending 2011-06-30).

3. Medicines Co. (MDCO): Provides various medicines to hospitals for advancing the treatment of critical care patients primarily in the United States and Europe. Market cap at $1.36B, most recent closing price at $25.35. The stock is trading 3.40% below its 52-week high. Revenue grew by 13.47% during the most recent quarter ($135.7M vs. $119.59M y/y). Accounts receivable grew by -2.86% during the same time period ($65.96M vs. $67.9M y/y). Receivables, as a percentage of current assets, decreased from 17.43% to 10.11% during the most recent quarter (comparing 3 months ending 2012-06-30 to 3 months ending 2011-06-30).

*Accounting data sourced from Google Finance, all other data sourced from Finviz.

Source: 3 Drugmakers Trading Near Highs With Strong Receivable Trends